ELTENAC

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H9Cl2NO2S
Molecular Weight	302.176
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC1=CSC=C1NC2=C(Cl)C=CC=C2Cl

InChI

InChIKey=AELILMBZWCGOSB-UHFFFAOYSA-N

InChI=1S/C12H9Cl2NO2S/c13-8-2-1-3-9(14)12(8)15-10-6-18-5-7(10)4-11(16)17/h1-3,5-6,15H,4H2,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C12H9Cl2NO2S
Molecular Weight	302.176
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://archive.apvma.gov.au/archive/gazette/2000/06/gazette0006p16.pdf
Curator's Comment: description was created based on several sources, including: http://www.in-farmacia.it/telzenac-fl-50ml.html | http://adisinsight.springer.com/drugs/800003785 | https://www.ncbi.nlm.nih.gov/pubmed/18674517

Eltenac is a compound with a structural similarity to diclofenac with one benzol ring substituted by a tiophene ring. This modification has been shown to improve the absorption after topical application. Eltenac is an inhibitor of both cyclo-oxygenase-1 and -2. Eltenac had been in phase II clinical trial for the treatment of osteoarthritis of the knee. Eltenac is used in the alleviation of inflammation associated with musculoskeletal disorders and control of post-operative swelling, oedema and endotoxaemia in horses. The local skin reactions reported in humans were erythema, eczema, itching, rash and dry skin.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11300751 \| https://www.ncbi.nlm.nih.gov/pubmed/18674517	Inhibitor 8504		0.03 µM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18674517 \| https://www.ncbi.nlm.nih.gov/pubmed/11300751	Inhibitor 8504		0.03 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Osteoarthritis 157 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11300751	Palliative	Phase II 1147	Unknown Approved Use Unknown
Musculoskeletal disorders 10 Sources: http://www.in-farmacia.it/telzenac-fl-50ml.html	Palliative	Approved 8583	Telzenac Approved Use For use in the alleviation of inflammation associated with musculoskeletal disorders and control of post-operative swelling, oedema and endotoxaemia in horses.
Post-operative swelling 1 Sources: http://www.in-farmacia.it/telzenac-fl-50ml.html	Preventing	Approved 8583	Telzenac Approved Use For use in the alleviation of inflammation associated with musculoskeletal disorders and control of post-operative swelling, oedema and endotoxaemia in horses.

AUC

Value	Dose	Co-administered	Analyte	Population
6.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9829405/	0.5 mg/kg bw 1 times / day multiple, oral dose: 0.5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:		ELTENAC plasma	Equus ferus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
6.77 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9829405/	0.5 mg/kg bw single, oral dose: 0.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		ELTENAC plasma	Equus ferus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9829405/	0.5 mg/kg bw 1 times / day multiple, oral dose: 0.5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:		ELTENAC plasma	Equus ferus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9829405/	0.5 mg/kg bw single, oral dose: 0.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		ELTENAC plasma	Equus ferus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9829405/	0.5 mg/kg bw 1 times / day multiple, oral dose: 0.5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:		ELTENAC plasma	Equus ferus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9829405/	0.5 mg/kg bw single, oral dose: 0.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		ELTENAC plasma	Equus ferus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis.	2001-04	11300751
Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel.	1997	9310109
Eltenac, a new anti-inflammatory and analgesic drug for horses: clinical aspects.	1991-06	1920607

Patents

Sample Use Guides

In Vivo Use Guide

Horses: 0.5 mg/kg (1 ml/100 kg) once daily for a period not exceeding 5 days.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:59 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:59 GMT 2025`
Record UNII	A153L3JA99
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TELZENAC

Preferred Name

English

ELTENAC

Official Name

English

eltenac [INN]

Common Name

English

ELTENAC [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257